Quarterly ResultMay 7, 2026, 04:26 PM
Janux Therapeutics Reports Q1 2026 Results; Receives $35M Milestone
AI Summary
Janux Therapeutics reported a net loss of $24.4 million for the first quarter of 2026, an increase from $23.5 million in the comparable period of 2025. The company maintained a strong cash position with $956.4 million in cash and short-term investments as of March 31, 2026. Key business highlights include receiving a $35 million milestone payment from its collaboration with Bristol Myers Squibb, advancing several clinical programs, and discontinuing the development of JANX008.
Key Highlights
- Net loss was $24.4 million for Q1 2026, compared to $23.5 million for Q1 2025.
- Cash and short-term investments totaled $956.4 million as of March 31, 2026.
- Achieved a development candidate nomination under Bristol Myers Squibb collaboration, triggering a $35 million milestone payment.
- Research and development expenses increased to $26.8 million for Q1 2026 from $25.1 million in Q1 2025.
- General and administrative expenses rose to $11.1 million for Q1 2026 from $9.8 million in Q1 2025.
- Initiated clinical evaluation of JANX014, a double-masked PSMA-TRACTr candidate.
- Discontinued development of JANX008 following completion of Phase 1a.
- Appointed William Go, M.D., Ph.D. as Chief Medical Officer.